文献速递系统性红斑狼疮

同种异体脐带来源间充质基质细胞治疗系统性红斑狼疮:单中心、开放标签、剂量递增1期研究

Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study.
PubMed 文献 · Lancet Rheumatol · 2024-12-17

这项在法国圣路易大学医院开展的前瞻性、单中心、开放标签、剂量递增贝叶斯1期研究,纳入8例对一线和二线治疗难治的重型系统性红斑狼疮(SLE)患者,接受单次静脉输注同种异体脐带来源间充质基质细胞(2×10^6或4×10^6个/kg)。输注后10天内无严重不良事件,仅2例发生3起输注相关不良事件(2起1级、1起2级)。作者认为2×10^6或4×10^6个/kg单次输注在重型SLE患者中是安全的,但需安慰剂对照试验确认临床疗效。

要点

  • 8例重型难治性SLE患者接受单次静脉输注2×10^6或4×10^6个/kg脐带间充质基质细胞,未发生治疗相关严重不良事件。
  • 输注后10天内2例发生3起输注相关不良事件(2起1级、1起2级),无严重不良事件。
  • 随访12.4个月(范围12-13)期间,1例复发后发生3起非治疗相关严重不良事件。

核心结论

  • 作者认为,单次输注2×10^6个/kg或4×10^6个/kg同种异体脐带来源间充质基质细胞在重型SLE患者中是安全的。
  • 作者指出,需要安慰剂对照试验来确认临床疗效以及B细胞改变在临床获益中的作用。

研究设计与样本

  • 前瞻性、单中心、开放标签、剂量递增、贝叶斯1期研究,在法国巴黎圣路易大学医院开展。
  • 纳入年龄18-70岁、符合美国风湿病学会SLE诊断标准且抗核抗体阳性、基线SELENA-SLEDAI评分≥6分、对一线和二线SLE治疗难治的患者。
  • 患者接受单次静脉输注1×10^6、2×10^6或4×10^6个/kg脐带来源间充质基质细胞(由单条脐带制备),每剂量组5例,从2×10^6个/kg起始。
  • 主要终点为输注后前10天内治疗相关严重不良事件(≥3级)的发生率。
  • 2019年5月14日至2023年3月6日筛查29例,最终入组8例,入组提前终止,无患者接受1×10^6剂量。

主要发现

  • 输注后前10天内无严重不良事件,2例患者发生3起输注相关不良事件(2起1级、1起2级)。
  • 随访12.4个月(范围12-13)期间,无治疗相关严重不良事件,1例患者复发后发生3起非治疗相关严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 入组提前终止,最终仅8例患者入组,无患者接受1×10^6个/kg剂量。
  • 作者指出需要安慰剂对照试验来确认临床疗效以及B细胞改变在临床获益中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with systemic lupus erythematosus (SLE) with inadequate responses to standard therapies have unmet therapeutic needs. The immunomodulatory, proangiogenic, and antifibrotic properties of mesenchymal stromal cells support their use in treating patients with SLE. We aimed to assess the safety of a single intravenous infusion of allogeneic umbilical cord-derived mesenchymal stromal cells in patients with severe SLE. METHODS: This prospective, single-centre, open-label, dose-escalation, Bayesian phase 1 study was done at the Saint-Louis University Hospital (Paris, France). Eligible patients were aged 18-70 years, were diagnosed with SLE according to American College of Rheumatology criteria with positive antinuclear antibodies, had a baseline Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score of 6 or more, and had disease that was refractory to first and second line SLE therapies. Patients were to receive a single intravenous infusion of 1 × 106, 2 × 106, or 4 × 106 umbilical cord-derived mesenchymal stromal cells per kg (manufactured from a single umbilical cord) in cohorts of five patients per dose, starting at 2 × 106 cells per kg. The primary endpoint was the rate of treatment-related severe adverse events (grade ≥3) in the first 10 days after infusion of umbilical cord-derived mesenchymal stromal cells. People with lived experience were involved in study design, patient enrolment, and dissemination of the study findings. This study is registered with ClinicalTrials.gov, NCT03562065, and the EU Clinical Trials Register, EudraCT2017-001400-29. FINDINGS: From May 14, 2019, to March 6, 2023, 29 patients were screened for eligibility, eight of whom were enrolled in the study. Enrolment was terminated early after inclusion of eight patients and no patients received the 1 × 106 dose of umbilical cord-derived mesenchymal stromal cells. Seven (88%) of eight participants were cisgender women and one (13%) was a cisgender man. The median age was 35 years (range 26-57) and the median SLE disease duration was 12 years (5-19). All patients received at least 2 × 106 cells per kg (range 2 × 106 to 4 × 106). No severe adverse events and three infusion-related adverse events (two grade 1 and one grade 2) occurred in two patients in the first 10 days after infusion. After 12·4 months (range 12-13) of follow-up, no treatment-related severe adverse events and three non-treatment-related severe adverse events occurred in one patient after relapse. INTERPRETATION: Our results suggest that a single infusion of 2 × 106 cells per kg or 4 × 106 cells per kg of allogeneic umbilical cord-derived mesenchymal stromal cells was safe in patients with severe SLE. Placebo-controlled trials are needed to confirm clinical efficacy and the role of B-cell modifications in clinical benefit. FUNDING: Fondation du Rein, Alliance Maladies Rares AFM-Téléthon, Direction de la Recherche Clinique et de l'Innovation AP-HP, and ANR eCellFrance.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Farge D, Biard L, Weil B, et al. Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study. Lancet Rheumatol. 2024. PMID: 39706212. doi:10.1016/S2665-9913(24)00298-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。